The Clinical Trials on Alzheimer's Disease Conference (CTAD) includes a focus on Alzheimer disease (AD) therapeutic trials, featuring leaders in AD research from industry and academia with an aim of forming partnerships to progress the development of effective treatments to fight the disease.
Pathing the Next Steps in Alzheimer Disease Research: Heather Snyder, PhD
January 8th 2024The vice president of medical and scientific relations at the Alzheimer’s Association discussed where the organization’s efforts are currently invested and the ways to continue momentum in the Alzheimer disease field. [WATCH TIME: 5 minutes]
Building on Momentum: Overviewing Ongoing Efforts from the Alzheimer’s Association
November 29th 2023Heather Synder, PhD, vice president of medical and scientific relations at the Alzheimer’s Association, gave thoughts on the recently concluded CTAD conference and how the organization plans to carry the positive momentum in the field.
Considerations Amid the Ever-Changing Field of Alzheimer Disease
November 28th 2023Alvaro Pascual-Leone, MD, PhD, director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, provided commentary on the ways Alzheimer disease treatment has changed and how clinicians will need to adapt in the coming years.
Mechanistic Potential of Synapse-Targeted Agent ALX-001 for Alzheimer Disease: Adam Mecca, MD, PhD
November 14th 2023The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]
Differences Between Antiamyloid Therapies Lecanemab and Donanemab: Martin Sadowski, MD, PhD
November 13th 2023The professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine commented on the differences in mechanisms and clinical trial data between lecanemab and donanemab. [WATCH TIME: 5 minutes]
Fosgonimeton's Impact on Neuroprotection and Cognition in Alzheimer Disease
November 12th 2023Kevin Church, PhD, chief scientific officer at Athira Pharma, discussed preclinical findings of fosgonimeton where the therapy exhibited procognitive effects among mice models in Alzheimer disease, as presented at CTAD 2023.
Overviewing Preliminary Data of ABvac40, a Vaccine for Alzheimer Disease: Jose Terencio, PhD
November 8th 2023The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]
NeuroVoices: Joseph Foss, MD, on NTRX-07 and CBR2-Targeting Therapies for Alzheimer Disease
November 8th 2023The chief medical officer of NeuroTherapia provided insight on promising phase 1b data assessing NTRX-07, a CBR2-targeting agent in development for patients with early-stage Alzheimer disease.
NeuroVoices: David Greeley, MD, on AR1001, an Oral PDE5 Inhibitor for Alzheimer Disease
November 1st 2023David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.
Reviewing the Phase 2 OVERTURE Results of Gamma Sensory Stimulation Device: Brent Vaughan
October 30th 2023The chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]
Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brent Vaughan
October 27th 2023The chief executive officer of Cognito Therapeutics provided an in-depth overview of the company’s gamma sensory stimulation device, its mechanism of action, and why it serves as a promising therapy for patients with Alzheimer disease. [WATCH TIME: 5 minutes]
Combination of Aducanumab Infusion and Focused Ultrasound Accelerates Reduction of Amyloid-ß Plaques
October 27th 2023The use of focused ultrasound-mediated blood-brain barrier opening has the potential to advance neurotherapeutics in the treatment of Alzheimer disease and other progreesive neurological disorder impacted by that barrier.
Mechanistic Potential of Pepinemab, a SEMA4D-Blocking Antibody: Terrence L. Fisher, PhD
October 26th 2023The senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]
AXS-05 Shows Reduction in Relapse Risk in Phase 3 ACCORD Trial for Alzheimer Disease Agitation
October 25th 2023Findings from the trial demonstrated rapid and sustained clinical response in patients with Alzhiemer disease agitation during the open-label treatment phase and did not show any new safety signals.
Therapeutic Advantages to Using EEG to Assess Alzheimer Agents: Williem de Haan, MD, PhD
October 25th 2023The neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]
Creating Innovative Ways to Improve Alzheimer Disease Prevention: Miia Kivipelto, MD, PhD
January 4th 2023The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease, and the new ways to approach prevention. [WATCH TIME: 4 minutes]